Madrigal Pharmaceuticals Inc. priced an underwritten registered public offering of 1,506,025 common shares at $83 apiece.
The company expects gross proceeds of about $125 million.
Madrigal granted underwriters a 30-day option to buy up to an additional 225,904 common shares.
The offering is expected to close by Dec. 21, subject to customary closing conditions.
Goldman Sachs & Co. LLC is acting as lead book-running manager for the offering, with Evercore ISI acting as book runner. JMP Securities, Roth Capital Partners and H.C. Wainwright & Co. are acting as co-managers for the offering.